From: sean.reilly@pharma.novartis.com
Sent: Friday, May 25, 2001 10:59 AM
To: fdadockets@oc.fda.gov
Cc: deborah.dickrath@pharma.novartis.com;
mathias.hukkelhoven@pharma.novartis.com;
james.carey@pharma.novartis.com; dorothy.watson@pharma.novartis.com
Subject: Docket No. 01N-0078

Dear Sir or Madam,
     Please accept these comments to Docket No. 01N-0078 submitted on
behalf of Novartis Pharmaceuticals Corporation.  These comments are
submitted after May 18 because the March 19, 2001 Federal Register Notice
did not indicate that the proposed surveys were available for review and we
have only recently obtained them from the FDA website.

     Sincerely,
     Sean Reilly
     Associate General Counsel
     Novartis Pharmaceuticals Corporation
     59 Route 10
     East Hanover, NJ  07936

(See attached file: DTC promotion of prescription drugs (Docket
OIN-0078).doc)